Abstract
Although an activating mutation of Ras is commonly observed in myelodysplastic syndrome (MDS), the role of Ras in the natural history of MDS remains largely unknown. We prospectively studied efficiency and tolerance of lonafarnib, a compound able to inhibit Ras signalling pathway through an inhibition of farnesyl transferase, in patients with MDS or secondary acute myeloid leukaemia (sAML). Lonafarnib was administered orally at a dose of 200 mg twice daily for three courses of 4 weeks (separated by 1 to 4 weeks without treatment). Sixteen patients were included: FAB/RAEB (n = 10), RAEB-T (n = 2), sAML (n = 2) and chronic myelomonocytic leukaemia (CMML; n = 2); WHO/RAEB-1 (n = 4), RAEB-2 (n = 5), AML (n = 5), CMML (n = 2). Median age was 70 (53–77) years. The karyotype was complex or intermediate in 11 patients, and the International Prognostic Scoring Systems (IPSS) risk groups were low in two patients, INT-1 in one patient, INT-2 in four patients and high in six patients (unknown or not applicable in three patients). Among the 14 patients tested, five had Ras mutations in codons 12, 13 or 61 of N-Ras, K-Ras or H-Ras. One patient was excluded of the analysis for protocol violation, and 15 patients were assessable for tolerance. Gastrointestinal toxicities (diarrhoea, nausea and anorexia) and myelosuppression were the major side effects. Other toxicities included infections, fatigue, increase of liver enzymes, arrhythmia and skin rash. One patient died of infection, and the treatment was stopped in one other who developed atrial fibrillation. Doses were reduced in all but one patient treated with more than one course of farnesyl transferase inhibitor. Responses were assessable in 12 patients. A partial response in one sAML patient and a very transient decrease of blast cell count with normalisation of karyotype in one MDS patient were observed. No relation between improvement of marrow parameters and detected Ras mutations was observed. Lonafarnib alone, administered following our schedule, has shown limited activity in patients with MDS or secondary AML. Gastrointestinal and haematological toxicities appear the limiting toxicity in this population of patients.
Similar content being viewed by others
References
Cheson BD, Bennet JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al (2003) Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloïd leukaemia. J Clin Oncol 21:4642–4649 doi:10.1200/JCO.2003.04.036
Cheson BD, Greenberg PL, Bennet JM, Lowenberg B, Wijermans PW, Nimer SD et al (2006) Clinical application and proposal for modification of the International working group (IWG) response criteria in myelodysplasia. Blood 108:419–425 doi:10.1182/blood-2005-10-4149
Eskens FA, Awada A, cutler DL, de Jonge MJ, Luyten GP, Faber MN, Statkevich P, Sparreboom A, Verweij J, Hanauske AR, Piccart M (2001) Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 19:1167–1175
Feldman EJ, cortes J, Holyoake TL, Simonsson B, De Angelo DJ, lipton JH, Turner AR, Baccarani M, barker J, Guilhot F, Petersdorf S, Silver RT, Wilson JM, Sugrue M, List AF (2003) Continuous oral Lonafarnib (Sarasarä) for the treatment of patients with myelodysplastic syndrome. Blood 102(11):421a
Fenaux P, Raza A, Mufti GJ, Aul C, Germing U, Kantarjian G et al (2007) A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 109:4158–4163 doi:10.1182/blood-2006-07-035725
Hirai H, Kobayashi Y, Mano H, Hagiwara K, Maru Y, Omine M et al (1987) A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature 327:430–432 doi:10.1038/327430a0
Horiike S, Misawa S, Nakai H, Kaneko H, Yokota S, Taniwaki M et al (1994) N-RAS mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia 8:1331–1336
Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K et al (2001) Clinical and biologic activity of farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 97:3361–3369 doi:10.1182/blood.V97.11.3361
Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF et al (2003) Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 102:4527–4534 doi:10.1182/blood-2002-11-3359
Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G et al (2004) Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 22:1287–1292 doi:10.1200/JCO.2004.08.082
Lancet JE, Karp JE (2003) Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 102:3880–3889 doi:10.1182/blood-2003-02-0633
Liu E, Hjelle B, Morgan R, Hecht F, Bishop JM (1987) Mutation of the Kirsten-ras proto-oncogene in human preleukemia. Nature 330:186–188 doi:10.1038/330186a0
Lübbert M, Mirro J Jr, Kitchingman G, McCormick F, Mertelsmann R, Hermann F et al (1992) Prevalence of N-RAS mutations in children with myelodysplastic syndromes and acute myeloid leukemia. Oncogene 7:263–268
Lyons J, Janssen JW, Bartram C, Layton M, Mufti GJ (1988) Mutations of Ki-RAS and N-RAS oncogenes in myelodysplastic syndromes. Blood 71:1707–1712
Padua RA, Guinn BA, Al-Sabah AI, Smith M, Taylor C, Pettersson T et al (1998) RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 12:887–892 doi:10.1038/sj.leu.2401044
Paquette RL, Landaw EM, Pierre RV, Kahan J, Lübbert M, Lazcano O et al (1993) N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 82:590–599
Raz T, Mohammad A, Daley GQ (2004) Resistance to the farnesyl transferase inhibitor SCH66336/Lonafarnib caused by mutations in the target protein farnesyl transferase beta. Blood 104(11):133a
Reuter CWM, Morgan MA, Bergmann L (2000) Targeting the Ras signalling pathway: a rational, mechanism-based treatment for hematologic malignancies. Blood 96:1655–1669
Acknowledgment
We sincerely thank Mrs. Anne De Meuter and Dominique De Poorter for their help in the organisation and follow-up of the study.
Author information
Authors and Affiliations
Corresponding author
Additional information
The experiments comply with laws of Belgium including ethics approval.
Rights and permissions
About this article
Cite this article
Ravoet, C., Mineur, P., Robin, V. et al. Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Ann Hematol 87, 881–885 (2008). https://doi.org/10.1007/s00277-008-0536-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-008-0536-2